«Центр ветеринарной помощи» (Главный ветеринарный врач)
Россия
ООО «АГ «Аспект» (Научный консультант)
ООО «НВП «Астрафарм» (Научный консультант)
Россия
ООО «НВП «Астрафарм» (Главный специалист по науке)
Россия
ООО «АГ «Аспект» (Ветеринарный врач)
ООО «НВП «Астрафарм» (Ведущий ветеринарный врач)
Россия
ГРНТИ 68.41 Ветеринария
Применение лекарственного препарата Курс Успокоин таблетки в минимальной начальной суточной дозе 7 мг/кг первые три дня, с дальнейшим увеличением минимальной суточной дозы до 14 мг/кг показало положительный эффект при коррекции поведения собак старше 10 лет с прогрессирующими признаками когнитивных нарушений.
сукцинат тразодона, Курс Успокоин таблетки, возрастные когнитивные нарушения, возрастные собаки, серотониновая система, нейромедиаторы
1. Landsberg G., Behavior problems of older cats, in Schaumburg I (ed), Proceedings of the 135th Annual Meeting of the American Veterinary Medical Associa-tion, San Diego, CA, 1998, pp. 317-320.
2. Gunn-Moore D.A., Moffat K., Christie L.A., et al., Cognitive dysfunction and the neurobiology of aging in cats, J Small Anim Pract, 2007, No. 48, pp. 546-553.
3. Goodenough J., McGuire B., Wallace R., Perspectives on animal behaviour. John Wiley & Sons, Inc., USA, 1993, 830 p.
4. De Boer S.F., Olivier B., Veening J., Koolhaas J.M., The neurobiology of of-fensive aggression: revealing a modular view, Physiology & Behavior, 2015, No. 146, pp. 111-127.
5. Fredrika R., The role of serotonin in animal personality. Linköping University | Department of Physics, Chemistry and Biology, 2017, p. 13.
6. Harvey P.J., Li X., Li Y., Bennett D.J., 5-HT2 receptor activation facilitates a persistent sodium current and repetitive firing in spinal motoneurons of rats with and without chronic spinal cord injury, J. Neurophysiol., 2006, No. 96, pp. 1158-1170. doi:https://doi.org/10.1152/jn.01088.2005.
7. Olivier B., Serotonin: a never-ending story, Eur. J. Pharmacol., 2015, No. 753, pp. 2-18.
8. Haider S., Khaliq S., Ahmed S.P., Haleem D.J., Long-term tryptophan administration enhances cognitive performance and increases 5-HT metabolism in the hippocampus of female rats, Amino Acids, 2006, No. 31, pp. 421-425.
9. Berger M., Gray J.A., Roth B.L., The Expanded Biology of Serotonin, Annu Rev Med. Author manuscript; available in PMC 2018 Mar 22.
10. Porter R.J., Lunn B.S., O’Brien J.T., Effects of acute tryptophan depletion on cognitive function in Alzheimer’s disease and in the healthy elderly. Psychol. Med., 2003, No. 33, pp. 41-49.
11. Mann J.J., Arango V., Underwood M.D., Serotonin and suicidal behavior. Ann NY Acad Sci, 1990, No. 600, pp. 476-485.
12. Štrac D.S., Pivac N., Mück-Šeler D., The serotonergic system and cognitive function. Transl Neurosc, 2016, May 9, No. 7(10, pp. 35-49.
13. Bacqué-Cazenave J., Bharatiya R., Barrière G., Delbecque J-P., Bouguiyoud N, Di Giovanni G.,Cattaert D., De Deurwaerdère Ph., Serotonin in Animal Cog-nition and Behavior/Int J Mol Sci., 2020 Mar, No. 21(5), pp. 1649.
14. Soubrié P., Reconciling the role of central serotonin neurons in human and animal behavior, Behav. Brain Sci., 1986, No. 9, pp. 319-335. DOI: 10.1017 / S0140525X00022871.
15. Bari A., Robbins T.W., Inhibition and impulsivity: Behavioral and neural basis of response control, Prog. Neurobiol., 2013, No. 108, pp. 44-79. doi:https://doi.org/10.1016/j.pneurobio.2013.06.005.
16. Perrier J.F., Cotel F., Serotonergic modulation of spinal motor control. Curr. Opin. Neurobiol., 2015, No. 33, pp. 1-7. doi:https://doi.org/10.1016/j.conb.2014.12.008.
17. Jacobs B.L., Azmitia E.C., Structure and function of the brain serotonin system. Physiol. Rev., 1992, No. 72, pp. 165-229. doi:https://doi.org/10.1152/physrev.1992.72.1.165.
18. Soubrié P., Reconciling the role of central serotonin neurons in human and animal behavior, Behav. Brain Sci., 1986, No. 9, pp. 319-335.
19. Rodriguez J.J., Noristani H.N., Verkhratsky A., The serotonergic system in ageing and Alzheimer’s disease. Prog. Neurobiol., 2012, No. 99, pp. 15-41.
20. Tsukada H, Kakiuchi T, Nishiyama S., Harada N. Effects of aging on 5-HT(1A) receptors and their functional response to 5-HT(1a) agonist in the living brain: PET study with [carbonyl-(11)C]WAY-100635 in conscious monkeys. Synapse 2001 Dec 15;42(4), pp. 242-251.doi:https://doi.org/10.1002/syn.10011.
21. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Au-toradiographic localization of 5-HT1A receptors in the postmortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res., 1997, No. 745, pp. 96-108.
22. Tauscher J., Verhoeff N.P., Christensen B.K., Hussey D., Meyer J.H., Kecojevic A., Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C] WAY-100635 and PET. Neuropsychopharmacology, 2001, No. 24, pp. 522-530.
23. Li Z., Ichikawa J., Dai J., Meltzer H.Y., Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol., 2004, No. 493, pp. 75-83.
24. Bantick R.A., De Vries M.H., Grasby P.M., The effect of a 5-HT1A receptor agonist on striatal dopamine release. Synapse, 2005, No. 57, pp. 67-75.
25. Blazer D., Williams C.D., Epidemiology of dysphoria and depression in the elderly population. Am J Psychiatry, 1980, No. 137, pp. 439-444.
26. Mann J.J., Arango V., Underwood M.D., Serotonin and suicidal behavior. Ann NY Acad Sci, 1990, No. 600, pp. 476-485.
27. Meltzer C.C., Smith G., De Kosky S.T., Pollock В.G., Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging, Neuropsychopharmacology, 1998, Vol. 18, pp. 407-430.
28. Kakiuchi T., Tsukada H., Fukumoto D., Nishiyama S., Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [11C] (1) McN5652 and [11C] (-) McN5652 in conscious monkeys, Synapse, 2001, No. 40, pp. 170-179.
29. Arora R.C., Gulati A., Crayton J.W., Aging and [3H] paroxetine binding in rat brain: effect of imipramine and tetrahydroacridine, Life Sci, 1993, No. 52, pp. 1767-1775.
30. Rood B.D., Calizo L.H., Piel D., Serotonin Neurons in Mice: Immature Hy-perexcitability Transitions to Adult State during First Three Postnatal Weeks Suggesting Sensitive Period for Environmental Perturbation, Journal of Neuroscience, 2014, Vol. 2 April, No. 34 (14), pp. 4809-4821; DOI: https://doi.org/10.1523/JNEUROSCI.1498-13.2014
31. Meltzer C.C., Smith G., De Kosky S.T., Pollock В.G., Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging, Neuropsychopharmacology, 1998, Vol. 18, pp. 407-430.
32. Simpson D.M., Foster D., Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry, 1986, No. 47, pp. 191-193.
33. Tingle D., Trazodone in dementia (letter), J Clin Psychiatry, 1986, No. 47, pp. 482.
34. Houlihan D.J., Mulsant B.H., Sweet R.A., et al., A naturalistic study of trazo-done in the treatment of behavioral complications of dementia. Am J Geriatr Psychiatry, 1994, No. 2, pp. 78-85.
35. Lebert F., et al., Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord., 2004, No. 17(4), pp. 355-359.
36. Cognitive disorder common in older dogs, URL: https://www.abqjournal.com/1005470/cognitive-disorder-common-in-older-dogs.html
37. Chea B., Giorgi М., Trazodone: A Review of Its Pharmacological Properties and Its Off-Label Use in Dogs and Cats, American Journal of Animal and Veterinary Sciences, 2017, No. 12 (4), pp. 188-194.
38. Gilbert-Gregory S.E., Stull J.W., Rice M.R., Herron M.E., Effects of trazodone on behavioral signs of stress in hospitalized dogs, J. Am. Vet. Med. Assoc., 2016, No. 249, pp. 1281-1291.
39. Gruen M.E., Roe S.C., Griffith E., Hamilton A., Sherman B.L., Use of trazodone to facilitate postsurgical confinement in dogs, J. Am. Vet. Med. Assoc., 2014, No. 245, pp. 296-301.
40. Hekman J.P., Karas A.Z., Sharp C.R., Psychogenic Stress in Hospitalized Dogs: Cross Species Comparisons, Implications for Health Care, and the Challenges of Evaluation Animals, 2014, No. 4(2), pp. 331-347.
41. Landsberg G. M., Nichol J., Araujo J. A. Cognitive Dysfunction Syndrome: a disease of canine and feline brain aging, Veterinary Clinics of North America: Small Animal Practice, 2012, No. 42(4), pp. 749-768.
42. Shin J.J., Saadabadi A., Trazodone. StatPearls Publishing, URL https://pubmed.ncbi.nlm.nih.gov/29262060/
43. Beasley C.M., Dornseif B.E., Pultz J.A., et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry, 1991, No. 52(7), pp. 294-299.
44. Cunningham L.A., Borison R.L., Carman J.S., et al., A comparison of venlafax-ine, trazodone, and placebo in major depression, J Clin Psychopharmacol., 1994, No. 14(2), pp. 99-106. doi:https://doi.org/10.1097/00004714-199404000-00003.
45. Kasper S., Olivieri L., Di Loreto G., Dionisio P., A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin., 2005, No. 21(8), pp. 1139-1146. doi:https://doi.org/10.1185/030079905X53243.
46. Moon C.A., Laws D., Stott P.C., Hayes G., Efficacy and tolerability of con-trolled-release trazodone in depression: a large multicentre study in general practice. Curr Med Res Opin., 1990, No. 12(3), pp. 160-168. doi:https://doi.org/10.1185/03007999009111497.
47. Munizza C., Olivieri L., Di Loreto G., Dionisio P., A comparative, random-ized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin., 2006, No. 22(9), pp. 1703-1713. doi:https://doi.org/10.1185/030079906X121039.
48. Sheehan D.V., Croft H.A., Gossen ER, et al., Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study, Psychiatry. 2009, No. 6(5), pp. 20-33.
49. Sheehan D.V., Rozova A., Gossen E.R., Gibertini M., The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull., 2009, No. 42(4), pp. 5-22.
50. van Moffaert M., de Wilde J., Vereecken A., et al., Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression, Int Clin Psychopharmacol. 1995, No. 10(1), pp. 3-9. doi:https://doi.org/10.1097/00004850-199503000-00001.
51. Weisler R.H., Johnston J.A., Lineberry C.G., et al., Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol., 1994, No. 14(3), pp. 170-179. doi:https://doi.org/10.1097/00004714-199406000-00004.
52. Blacker R., Shanks N.J., Chapman N., Davey A., The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline, Psychopharmacology, 1988, No. 95(Suppl), S18-S24.
53. Botros W.A., Ankier S.I.., Priest RG., et al., Clinical assessment and perfor-mance tasks in depression: a comparison of amitriptyline and trazodone. Br J Psychiatry, 1989, No. 155, pp. 479-482. doi:https://doi.org/10.1192/bjp.155.4.479.
54. Davey A., A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology, 1988, No. 95(Suppl), S25-S30.
55. Debus J.R., Rush A.J., Himmel C., et al., Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry, 1988, No. 49(11), pp. 422-426.
56. Pan Y., Landsberg G., Mougeot I., Kelly S., Xu H., Bhatnagar S., Milgram N.W., (2018). Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study. URL https://www.frontiersin.org/articles/10.3389/fnut.2018.00127/full
